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The National Cholesterol Education Program’s Adult Treat-ment Panel III report (ATP III)1 identified the metabolic
syndrome as a multiplex risk factor for cardiovascular disease
(CVD) that is deserving of more clinical attention. Subsequently,
the National Heart, Lung, and Blood Institute (NHLBI), in
collaboration with the American Heart Association (AHA),
convened a conference to examine scientific issues related to
definition of the metabolic syndrome.2 The present report sum-
marizes a second conference devoted to clinical management of
the metabolic syndrome, which was sponsored by the AHA in
partnership with the NHLBI and cosponsored by the American
Diabetes Association (ADA). This latter conference considered
the following issues: (1) pathogenesis and presentation of the
metabolic syndrome, (2) management of underlying risk factors,
(3) management of metabolic risk factors, and (4) unresolved
issues and research challenges.
The conference on definition2 confirmed CVD as a major
clinical outcome of metabolic syndrome and identified 6 major
components of the syndrome: abdominal obesity, atherogenic
dyslipidemia, elevated blood pressure, insulin resistance 
glucose intolerance, a proinflammatory state, and a prothrom-
botic state. The follow-up conference on management was
structured around therapies for these components. Clinical rec-
ognition of the metabolic syndrome is generally based on finding
several well-recognized signs in clinical practice: abdominal
obesity, elevated triglycerides, reduced HDL cholesterol, raised
blood pressure, and elevated plasma glucose. In addition, re-
search shows that other components not routinely measured
commonly aggregate with the major components: elevated
apolipoprotein B, small LDL particles, insulin resistance and
hyperinsulinemia, impaired glucose tolerance (IGT), elevated
C-reactive protein (CRP), and variation in coagulation factors
(eg, plasminogen activator inhibitor [PAI]-1 and fibrinogen).
The conference on definition2 also emphasized that risk for type
2 diabetes is higher in persons with metabolic syndrome and that
diabetes is a major risk factor for CVD. It also examined various
criteria for a clinical diagnosis of the metabolic syndrome. The
diagnostic scheme developed by ATP III is shown in the Table.
Clinical criteria proposed by the World Health Organization3
and American Association of Clinical Endocrinologists4 also
were reviewed. These latter criteria overlap with those of ATP
III but differ by requiring direct evidence of insulin resistance for
diagnosis. Both the World Health Organization and the Ameri-
can Association of Clinical Endocrinologists recommend an oral
glucose tolerance test (OGTT) in patients without an elevated
fasting glucose. In other words, in the absence of impaired
fasting glucose (IFG), IGT detected by OGTT is considered as
one metabolic risk factor defining the metabolic syndrome. ATP
III does not recommend OGTT in such persons, even through
IGT is a high-risk condition for type 2 diabetes (independent of
IFG) and correlates with increased risk for CVD. ATP III,
however, held that the information gained by OGTT does not
outweigh its costs and inconvenience in routine practice. The
present conference on management moved from the issue of
definition of the metabolic syndrome to the wide issues of
clinical management.
Presentation and Pathogenesis of
Metabolic Syndrome
Presentation of Metabolic Syndrome
Characteristics of the metabolic syndrome occur in some
children and adolescents, but prevalence of the metabolic
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syndrome increases with age. The highest prevalence is
observed in older persons, although frequency rises rapidly in
middle age and parallels, with some lag time, the develop-
ment of obesity in the population. In the United States,
approximately one third of overweight/obese persons mani-
fest the metabolic syndrome according to ATP III diagnosis
criteria.5 Several ethnic groups, including Hispanics and
South Asians (eg, from the Indian subcontinent), seem to be
particularly susceptible to the syndrome. Black men have a
lower frequency of the syndrome than do white men, likely
because of a lower prevalence of atherogenic dyslipidemia;
nonetheless, black men are unusually susceptible to hyper-
tension and carry a greater risk for diabetes. The genetic
underpinning of metabolic syndrome is a topic of growing
interest. In rare instances, patients have severe metabolic
syndrome because of monogenic disorders such as adipose
tissue disorders (eg, lipodystrophy caused by mutations in
lamin A/C, AGPAT, and seipin). Polymorphisms in a variety
of genes have been reported to associate with the metabolic
syndrome, but their contributions to the syndrome in the
general public remain to be determined. The metabolic
syndrome increasingly is being recognized as a side effect of
several commonly used drugs, mainly because some of these
drugs (eg, corticosteroids, antidepressants, antipsychotics,
antihistamines) can produce weight gain, which predisposes
to 2 of the features of the metabolic syndrome: obesity and
glucose intolerance. Protease inhibitors used in the treatment
of HIV very often induce a metabolic syndrome secondary to
lipodystrophy and insulin resistance. More commonly, the
metabolic syndrome associates with abdominal obesity, the
form of obesity that often develops in middle age. An excess
of visceral fat may be particularly pathogenic, but abdominal
subcutaneous adipose tissue likely contributes as well, as can
total body fat.
Pathogenesis of Metabolic Syndrome
The conference on the definition of the metabolic syndrome2
identified 3 potential etiologic categories: (1) obesity and
disorders of adipose tissue, (2) insulin resistance, and (3) a
constellation of independent factors (eg, molecules of he-
patic, vascular, and immunologic origin) that mediate specific
components of the syndrome. Both genetic and acquired
causes were determined to play a role in each. These 3
potential etiologic categories were examined in the present
conference. In clinical and epidemiological studies, obesity is
strongly associated with all cardiovascular risk factors. Adi-
pose tissue is recognized as a source of several molecules that
are potentially pathogenic: excess nonesterified fatty acids,
cytokines (tumor necrosis factor-), resistin, adiponectin,
leptin, and PAI-1. Visceral adipose tissue may be particularly
active in producing several of these factors. However, the
mechanisms underlying the association between abdominal
obesity (particularly visceral obesity) and the metabolic
syndrome are not fully understood and likely are complex. It
has been assumed that obese adipose tissue releases an excess
of fatty acids and cytokines that induce insulin resistance;
however, there is growing recognition that this concept,
although undoubtedly containing truth, is an oversimplifica-
tion of the interactions among obesity, body fat distribution,
and cardiovascular risk factors.
The second pathogenic category, insulin resistance, is
widely believed to be at the heart of the metabolic syndrome,
even though there is as yet little clinical trial evidence that a
reduction in insulin resistance will substantially improve any
of the components of the metabolic syndrome other than
glucose intolerance. Thus, the mechanistic link between
insulin resistance and most of the components of the meta-
bolic syndrome remains unclear. Although insulin resistance
is strongly associated with atherogenic dyslipidemia and a
proinflammatory state, it is less tightly associated with
hypertension and the prothrombotic state. Finally, some data
support the concept that insulin resistance or its associated
hyperinsulinemia are independent risk factors for CVD, but
this association has not yet been confirmed in controlled
studies.
Much of the heterogeneity in the manifestation of the
metabolic syndrome may therefore be due to the fact that
many of the component factors are regulated independently
of insulin resistance. Lipoprotein metabolism is regulated by
genetic factors as well as by diet composition, and both can
worsen atherogenic dyslipidemia. Blood pressure regulation
is similarly complex and affected by dietary factors, physical
activity, and renal/adrenal organ function. Only some persons
with obesity and/or insulin resistance develop type 2 diabetes;
for diabetes to appear, independent defects in beta-cell
function must be present.
Other important modifiers also influence clinical expres-
sion of the metabolic syndrome. For example, physical
inactivity promotes the development of obesity and modifies
muscle insulin sensitivity. Aging is commonly accompanied
by a loss of muscle mass and by an increase in body fat,
ATP III Clinical Identification of the Metabolic Syndrome
Risk Factor Defining Level
Abdominal obesity, given as waist circumference*†
Men 102 cm (40 in)
Women 88 cm (35 in)
Triglycerides 150 mg/dL
HDL cholesterol
Men 40 mg/dL
Women 50 mg/dL
Blood pressure 130/85 mm Hg
Fasting glucose 110 mg/dL‡
*Overweight and obesity are associated with insulin resistance and the
metabolic syndrome. However, the presence of abdominal obesity is more
highly correlated with the metabolic risk factors than is an elevated BMI.
Therefore, the simple measure of waist circumference is recommended to
identify the body weight component of the metabolic syndrome.
†Some male patients can develop multiple metabolic risk factors when the
waist circumference is only marginally increased, eg, 94 to 102 cm (37 to 39
in). Such patients may have a strong genetic contribution to insulin resistance.
They should benefit from changes in life habits, similarly to men with
categorical increases in waist circumference.
‡The American Diabetes Association has recently established a cutpoint of
100 mg/dL, above which persons have either prediabetes (impaired fasting
glucose) or diabetes.16 This new cutpoint should be applicable for identifying
the lower boundary to define an elevated glucose as one criterion for the
metabolic syndrome.
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particularly accumulation of fat in the abdomen; both changes
can increase insulin resistance. Moreover, recent studies
suggest that aging is accompanied by specific defects in fatty
acid oxidation in muscle, also enhancing insulin resistance.
Hyperandrogenemia has been associated with insulin resis-
tance in women with polycystic ovary disease. Furthermore,
mild hypercorticoidism has been implicated in development
of abdominal obesity.
Management of Underlying Risk Factors
The underlying risk factors that promote development of the
metabolic syndrome are overweight and obesity, physical
inactivity, and an atherogenic diet. All current guidelines on
the management of the individual components of the meta-
bolic syndrome emphasize that lifestyle modification (weight
loss and physical activity) is first-line therapy. ATP III
introduced the concept of the metabolic syndrome into its
cholesterol guidelines in an attempt to highlight the need for
more intensive lifestyle therapy as a means to prevent CVD in
higher-risk patients. Conference participants supported this
emphasis, whereas drug therapy was considered secondary, if
at all, unless otherwise indicated by current CVD prevention
guidelines.
Overweight and Obesity
In 1998, an expert panel was commissioned by the NHLBI
and National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) to produce evidence-based guidelines on
clinical management of overweight and obesity. This panel6
defined overweight and obesity as body mass indexes of 25 to
29.9 kg/m2 and 30 kg/m2, respectively. Abdominal obesity,
defined as a waist circumference 102 cm (40 inches) in
men and 88 cm (35 inches) in women, was identified as
being particularly associated with several of the components
of the metabolic syndrome. For this reason, ATP III recom-
mended that abdominal obesity be considered one of the risk
factors for the metabolic syndrome. It must be remembered
that individuals can have the metabolic syndrome with a
lesser degree of or no abdominal obesity if 3 of the remaining
components are found. Such individuals are common in
certain ethnic groups, such as Asians.
Obesity guidelines6 stress the need for weight reduction
using behavioral change to reduce caloric intake and increase
physical activity. Years of study and clinical experience have
revealed several key points about weight loss and weight
management. The first is that “crash diets” and “extreme
diets” are seldom effective in producing long-term weight
reduction. Such diets include very low-calorie diets and
high-fat/low-carbohydrate diets. More effective and healthful
for long-term weight loss are reduced-energy diets, consisting
of a modest 500- to 1000-calorie/day reduction. A realistic
goal for weight reduction is to reduce body weight by 7%
to 10% over a period of 6 to 12 months. Long-term mainte-
nance of weight loss is then best achieved when regular
exercise is included in the weight-reduction regimen. The
emphasis in behavioral change should include improvements
in eating habits (eg, setting goals, planning meals, reading
labels, eating regular meals, reducing portion sizes, self-
monitoring, avoiding eating binges). Emphasis should be
placed on the benefit of social support, stress management,
and the value of a regular exercise regimen. Although
knowledge and education are critical, they are insufficient,
and thus professional support (eg, nutrition counseling) is
often very helpful. Detailed advice for weight reduction can
be obtained from obesity guidelines at http://www.nhlbi.
nih.gov and http://www.americanheart.org.
Physical Inactivity
Approximately 70% of the US public can be classified as
being sedentary. Regular exercise and fitness have been
shown to improve several metabolic risk factors and are
associated with a reduction in the risk of developing many
chronic diseases. For these reasons, physical inactivity must
be considered to be an important contributor to the develop-
ment of the metabolic syndrome.7 Current physical activity
guidelines7 recommend practical, regular, and moderate reg-
imens for exercise. The standard exercise recommendation is
a daily minimum of 30 minutes of moderate-intensity phys-
ical activity. Increasing the level of physical activity appears
to further enhance beneficial effect. Suggestions that may
help to initiate and maintain a regular exercise regimen
include incorporating multiple short (10- to 15-minute) bouts
of activity (brisk walking), avoiding common sedentary
activities in leisure time (television watching and computer
games), purchasing simple exercise equipment for the home
(eg, treadmills), adding regular exercise into daily schedule
(eg, brisk walking, jogging, swimming, biking, golfing, team
sports), and self-monitoring of exercise. More exercise (ie, 1
hour daily) is even more efficacious for weight control.
Because of the relation between physical inactivity and the
metabolic syndrome, management of the latter should include
initiation of a program of regular physical activity. As already
mentioned, physical activity is one modality associated with
successful weight reduction, particularly for weight mainte-
nance. Conference participants reviewed several clinical trials
that showed that the combination of weight reduction and
increased physical activity can halve progression to new-
onset diabetes over a period of several years in persons with
prediabetes, defined as IFG or IGT. Whether weight reduc-
tion together with regular exercise will reduce risk for CVD
has not been adequately tested in controlled clinical trials;
nonetheless, epidemiological data are supportive, and the
favorable effects of weight reduction and exercise on CVD
risk factors provide strong support and justification for
recommending them as part of a regimen to reduce risk for
CVD.
Dietary Modification
ATP III recommendations for diet composition for patients
with metabolic syndrome are consistent with general dietary
recommendations.8–10 These guidelines call for low intake of
saturated fats, trans fats, and cholesterol; reduced consump-
tion of simple sugars; and increased intakes of fruits, vege-
tables, and whole grains. An important question is whether
patients with metabolic syndrome will benefit from a shift to
relatively more unsaturated fats. Very high-carbohydrate
diets may accentuate atherogenic dyslipidemia, and this risk
factor is reduced by isocalorically substituting a higher intake
of unsaturated fats. The clinical significance of diet-induced
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atherogenic dyslipidemia, however, is undetermined. Recent
small clinical trials indicate that improvement of atherogenic
dyslipidemia by increasing unsaturated fat consumption is
relatively small when compared with standard dietary
recommendations.8,9
Management of Metabolic Risk Factors
Although therapeutic lifestyle modification is first-line ther-
apy for the metabolic syndrome and thus deserves initial
attention, drug therapy may be necessary in many patients to
achieve recommended goals. Risk assessment in patients with
metabolic syndrome is critical for setting goals of therapy.
Risk Assessment
In the conference on definition of metabolic syndrome,2
investigators from the Framingham Heart Study showed that
the standard Framingham risk equations, which include
cigarette smoking, blood pressure, total cholesterol, HDL
cholesterol, and age, capture most of the risk for CVD in
patients with the metabolic syndrome. Adding abdominal
obesity, triglycerides, and fasting glucose to these equations
provides little or no increase in power of prediction. Whether
adding other parameters that contribute to the components of
the metabolic syndrome—apolipoprotein B, small LDL,
CRP, fibrinogen—to these risk equations will improve pre-
diction of coronary heart disease (CHD) risk has not been
tested extensively. At present, therefore, a practical approach
to estimating CHD/CVD risk in patients with the metabolic
syndrome is to use the standard Framingham algorithm. The
risk of developing diabetes is highly dependent on the
presence of obesity and IFG—2 components of the syndrome.
Whether to carry out OGTT in persons with obesity and/or
IFG was debated. Obtaining the 2-hour value in an OGTT
may increase the likelihood of finding that a patient already
has diabetes or IGT. The presence of IGT signifies increased
risk for developing diabetes. Framingham data, however, fail
to show independent predictive power of IGT for CVD,
although diabetes definitely raises CVD risk. Therefore,
OGTT adds power only for detecting or predicting diabetes
but not CVD. Moreover, oral glucose testing is inconvenient
and adds cost to evaluation. Finally, persons who have
diabetes only diagnosed by an OGTT will likely develop
diabetes diagnosed by fasting plasma glucose in a relatively
short time, and it is unclear whether the hiatus will be
clinically meaningful. Therefore, OGTT is not now widely
recommended as routine for obese persons who have the
metabolic syndrome but must be placed in the category of
optional testing based on clinical judgment.
Atherogenic Dyslipidemia
Beyond lifestyle modification, several drug alternatives may
be considered in patients with atherogenic dyslipidemia. ATP
III emphasized that LDL cholesterol is the primary target of
lipid-lowering therapy. Statins will reduce all apolipoprotein
B–containing lipoproteins and often can achieve the ATP III
goals for LDL cholesterol as well as for non-HDL cholester-
ol. Several clinical trials have confirmed the benefit of statin
therapy.1 Fibrates improve all components of atherogenic
dyslipidemia and appear to reduce the risk for CVD.1 Their
use in combination with statins is particularly attractive.
However, both fibrates and statins have the potential to
produce myopathy, and when they are used together, risk for
myopathy is enhanced.11 The literature contains many iso-
lated reports of severe myopathy occurring from the combi-
nation of statin plus gemfibrozil. Recent evidence further
indicates that gemfibrozil interferes with catabolism of statins
in the liver, which can raise statin blood levels, thereby
predisposing to myopathy. Fenofibrate does not interact
adversely with statin catabolism and thus may be safer to use
in combination therapy. Nicotinic acid has similar features to
fibrates, and the combination of nicotinic acid and statins is
promising. Nicotinic acid is especially efficacious for raising
HDL cholesterol levels, but higher doses can raise plasma
glucose levels. Therefore, if nicotinic acid is used in patients
with IFG, IGT, or diabetes, its dose should be kept relatively
low (eg, 1 to 2 g per day).
Elevated Blood Pressure
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7)12 introduced a new category of
“prehypertension” (120 to 139/80 to 89 mm Hg), in recogni-
tion of the fact that underlying risk factors raise blood
pressure to ranges that increase risk for CVD. This recogni-
tion accords with ATP III’s adding of blood pressures
130/85 mg/dL to the list of risk factors comprising the
metabolic syndrome. In persons with categorical hyperten-
sion (blood pressure 140/90 mm Hg), drug therapies are
required according to JNC 7 recommendations. In patients
with established diabetes, antihypertensive drugs should be
introduced at even lower blood pressures (130/
80 mm Hg). No particular antihypertensive agents have
been identified as being preferable for hypertensive patients
who also have the metabolic syndrome. Diuretics and
-blockers in high doses can worsen insulin resistance and
atherogenic dyslipidemia. For thiazide diuretics, doses should
be kept relatively low in accord with current recommenda-
tions. -Blockers are cardioprotective in patients with estab-
lished CHD and are no longer contraindicated in patients with
type 2 diabetes. Angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers are useful antihypertensive
drugs, and some clinical trials (but not all) suggest that they
carry advantages over other drugs in patients with diabetes.
At this time, however, the majority of clinical trials indicate
that most of the risk reduction associated with antihyperten-
sive drugs is the result of blood pressure lowering alone.
Insulin Resistance and Hyperglycemia
There is growing interest in the possibility that drugs that
reduce insulin resistance will delay onset of type 2 diabetes
and will reduce CVD risk when the metabolic syndrome is
present. The Diabetes Prevention Program showed that met-
formin therapy in patients with prediabetes will prevent or
delay the development of diabetes. Data on use of the
thiazolidinedione troglitazone suggested a similar effect, but
this drug has been withdrawn from commercial use. Although
insulin resistance is associated with increased CVD risk,
neither metformin nor any of the thiazolidinediones now on
the market have been shown to reduce the risk of CVD in
those with the metabolic syndrome, prediabetes, or diabetes.
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Thus, there is insufficient evidence to recommend these drugs
for anything other than their glucose-lowering action.
The presence of the metabolic syndrome in patients with
type 2 diabetes conveys a particularly high risk for CVD.
When both are present, appropriate treatment of dyslipidemia
and hypertension is essential. Good glycemic control is also
important because of the evidence suggesting that a reduction
in A1C level to 7.0% or less will reduce CVD events. Choice
of drug therapy beyond lifestyle changes to achieve this
glycemic goal depends on clinical judgment.
Prothrombotic State
A prothrombotic state in patients with the metabolic syn-
drome is characterized by elevations of fibrinogen, PAI-1,
and possibly other coagulation factors. However, these are
not measured routinely in clinical practice. The risk for
thrombotic events can be reduced by aspirin therapy. The
AHA currently recommends use of aspirin prophylaxis in
most patients whose 10-year risk for CHD is 10% as
determined by Framingham risk scoring.13 Including patients
with metabolic syndrome when their 10-year risk for CHD is
10% is appropriate.
Proinflammatory State
This condition is characterized by elevated cytokines (eg,
tumor necrosis factor- and interleukin-6) as well as by
elevations in acute-phase reactants (CRP and fibrinogen).
Measurement of CRP is the most practical way to assess the
presence of an inflammatory state. CRP levels tend to be
higher than normal in patients with the metabolic syndrome.
An elevated CRP (3 mg/L) is an emerging risk factor for
CVD.1 The AHA and Centers for Disease Control and
Prevention (CDC)14 recently issued guidelines for measure-
ment of CRP in clinical practice. They suggested that such
measurements can be made at the physician’s discretion, but
testing should be limited to individuals assessed to be at
intermediate risk by Framingham scoring, ie, those whose
10-year risk for CHD is in the range of 10% to 20%. The
purpose of CRP testing in an intermediate-risk patient is to
find those with high CRP levels whose risk category should
be raised to high. The practical consequences of elevating the
risk category would be to intensify lifestyle therapies, make
certain that low-dose aspirin is used, and set lower LDL
goals. AHA/CDC guidelines emphasized that CRP testing
still belongs in the category of optional based on clinical
judgment rather than recommended routinely because the
magnitude of its independent predictive power remains
uncertain.15
Major Conclusions
The metabolic syndrome consists of a constellation of factors
that raise the risk for CVD and type 2 diabetes. Because of the
increasing prevalence of obesity in the United States, the
metabolic syndrome has increased in frequency. ATP III
introduced the metabolic syndrome into its clinical guidelines
in the effort to achieve CVD risk reduction beyond LDL-
lowering therapy. Other clinical guidelines likewise have
emphasized the need for more clinical attention to the
metabolic syndrome.
Although not all obese, sedentary persons acquire the
metabolic syndrome, a significant subgroup of the population
is susceptible to worsening of important contributors to the
metabolic syndrome in the presence of energy imbalance.
Several factors appear to contribute to this susceptibility,
especially genetic predisposition and aging. Certain ethnic
groups are particularly susceptible to the syndrome. Insulin
resistance is a common feature of many of the components of
the metabolic syndrome, and some investigators believe that
it plays a key pathogenic role. Although genetic susceptibility
is essential, the metabolic syndrome is relatively uncommon
in the absence of obesity and physical inactivity. For this
reason, lifestyle modification leading to weight reduction and
increased physical activity represents first-line clinical ther-
apy of the metabolic syndrome. Practical approaches to both
were considered in depth in the conference. Smoking cessa-
tion, of course, is paramount. A realistic goal for overweight/
obese persons is to reduce body weight by 7% to 10% over
a period of 6 to 12 months. Weight reduction should be
combined with a daily minimum of 30 minutes of moderate-
intensity physical activity. Nutritional therapy calls for a low
intake of saturated fats, trans fats, and cholesterol; reduced
consumption of simple sugars; and increased intakes of fruits,
vegetables, and whole grains. Extremes in intakes of either
carbohydrates or fats should be avoided.
In addition, it was recognized that when genetic influences
are particularly strong or when lifestyle changes fail to reduce
risk sufficiently, drug therapy might be required to achieve
treatment goals recommended in current guidelines. Particu-
lar attention must be given to adequately controlling the other
major CVD risk factors: cigarette smoking, hypertension,
elevated LDL cholesterol, and diabetes. Standard therapies
for each apply in patients with the metabolic syndrome. Use
of combination therapy with fibrates or nicotinic plus a statin
is attractive for metabolic-syndrome patients with athero-
genic dyslipidemia; even so, efficacy over statins alone has
not been documented through clinical trials. Low-dose aspirin
to modify the prothrombotic–proinflammatory state is justi-
fied for patients at intermediate risk and high risk. To date,
management of insulin resistance with insulin-sensitizing
agents in the absence of diabetes has not been shown to
reduce CVD risk; therefore, they cannot be recommended for
this purpose.
Unresolved Issues: Future Research Challenges
The conference highlighted several unresolved issues that
should receive attention. These include the following for
patients with the metabolic syndrome:
1. Improved strategies for successful weight reduction and
maintenance and increased physical activity
2. A better understanding of the genetic and metabolic
contributions leading to the development of the
syndrome
3. Improved risk assessment for CVD
4. The value of treating atherogenic dyslipidemia beyond
LDL-lowering therapy
5. The efficacy of treating insulin resistance for reducing
the risk of CVD
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6. A better understanding of the relationship between a
proinflammatory state and the metabolic syndrome and
the efficacy of intervention on this state for the preven-
tion of both CVD and diabetes
7. Establishment of benefit and cost-effectiveness of spec-
ified goals for drug therapies directed toward the
metabolic syndrome as a whole or particular risk
components
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